Anti-Human IL-5Rα (CD125) (Benralizumab) (I-2200-50mg)

Eosinophilic inflammation underlies certain asthma and chronic obstructive pulmonary disease(COPD) phenotypes1. IL-5 is the primary cytokine mediating eosinophil mobilization,maturation, activation and survival2. Neutralization of IL-5 in murine and nonhuman primatemodels of asthma results in reduced eosinophil counts and improved lung pathology. Therefore,strategies that deplete lung eosinophils and basophils have been sought to improve asthmacontrol. IL-5Rα was selected as a suitable target because its expression is restricted toeosinophils, basophils and their progenitors in bone marrow. Benralizumab is a humanized, monoclonal antibody that binds to an epitope indomain 1 of IL-5Rα that overlaps with a portion of the IL-5 binding site1,2. Residue I61 is criticalfor benralizumab binding2. Binding inhibits IL-5 receptor signaling independent of the ligandand leads to depletion of eosinophils as well as inhibition of IL-5-mediated cell proliferation1.Additionally, in vitro, benralizumab potently induces apoptosis of eosinophils and basophils viaantibody-dependent cell-mediated cytotoxicity in the presence of NK effector cells2. Incynomolgus monkeys, benralizumab depletes blood and lung eosinophils as well as eosinophilprecursors present in bone marrow. Benralizumab has been approved for the treatment of eosinophilic asthma and chronicobstructive pulmonary disease1. This product is for research use only.